iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-
NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), and the American Society of Transplant Surgeons (ASTS) today announced the selection of Kenneth Andreoni, MD, Surgical Director of Kidney Transplantation at Thomas Jefferson University, and Kenneth Chavin, MD, MBA, PhD, FACS, of Temple Health, as the recipients of the ASTS-iMDx Research Grant for Understanding the Health Economics of In-House versus Send-Out of donor-derived cell-free DNA (dd-cfDNA) testing. The pursuit of this research is timely as the transplant community increasingly considers adopting in-house dd-cfDNA testing, and rigorous economic and outcomes data is essential to guide transplant programs in making informed decisions about their laboratory infrastructure and assay selection.
The $100,000 grant will be administered through ASTS and funded by iMDx. This health econometric research will compare the costs, clinical impact, and operational implications of in-house diagnostic testing versus send-out centralized laboratory testing. The results of this independent econometric study will generate important information to support future commercialization planning for GraftAssureDx™, which is currently under FDA review.
About the ASTS-iMDx Health Economics Research Grant Recipients
Dr. Andreoni serves as Surgical Director of Kidney Transplantation at Thomas Jefferson University and brings deep clinical and administrative expertise to the evaluation of transplant program operations and diagnostic testing strategies. Dr. Chavin holds appointments at Temple Health and has a unique interdisciplinary perspective informed by his combined training in medicine, business, and science. Together, the grant recipients offer complementary experience in transplant surgery, health systems management, and clinical research that positions this project to generate meaningful and actionable insights for the transplant field.
"We are very pleased to announce Drs. Andreoni and Chavin as the recipients of this grant," said iMDx CEO Josh Riggs. "Both physicians have outstanding experience and credibility in the field of transplantation, and we are confident that their research will advance the community's understanding of the real-world economics of in-house diagnostics. We are also grateful for the opportunity to partner with the American Society of Transplant Surgeons on this important program. As more transplant centers explore in-house dd-cfDNA testing, having rigorous health economic data will be critical to helping programs evaluate their options and plan accordingly."
"The question of whether to perform dd-cfDNA testing in-house or through a centralized laboratory is one that many transplant programs are actively grappling with," said Dr. Kenneth Chavin of Temple Health. "This grant gives us the opportunity to develop a rigorous economic model that will help transplant centers think through the true costs and benefits of each approach. We look forward to producing research that can serve as a practical resource for the community."
"In-house testing has the potential to meaningfully improve turnaround times and, ultimately, patient care," said Dr. Kenneth Andreoni, Surgical Director of Kidney Transplantation at Thomas Jefferson University. "But making the case for that investment requires data. We are excited to conduct this research in partnership with ASTS and iMDx and to contribute evidence that transplant programs can use as they evaluate their diagnostic testing strategies."
ASTS and iMDx established the grant to support research that compares the total cost of care, return on investment, clinical outcomes, and operational efficiency associated with in-house versus send-out transplant testing. Proposed studies are encouraged to utilize advanced econometric modeling such as Markov models, decision-tree analysis, or instrumental variable approaches.
iMDx Transplant Products and Product Candidates in Development
iMDx's flagship GraftAssure™ technology quantifies dd-cfDNA, a molecular biomarker of kidney transplant rejection that has been validated in peer-reviewed studies across leading academic transplant centers around the world. The Company’s scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection. Under the GraftAssure™ brand, iMDx’s transplant diagnostics include the following:
- GraftAssureCore – The company’s laboratory-developed test (LDT), currently reimbursed by CMS and performed at iMDx’s CLIA-certified laboratory in Franklin, Tenn.
- GraftAssureIQ – A research-use-only (RUO) kit intended and labeled for non-clinical applications.
- GraftAssureDx – iMDx has submitted GraftAssureDx™, a kitted in vitro diagnostic for clinical decision-making, to the FDA for regulatory review under the Class II de novo pathway.
About Insight Molecular Diagnostics, Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™, and iMDx™ are trademarks of Insight Molecular Diagnostics, Inc.
Forward-Looking Statements
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the expected outcomes and findings of the ASTS-iMDx grant research, the company's plans to deliver GraftAssureDx as an industry-leading molecular diagnostic kit for clinical use, the FDA's review of iMDx's submission of GraftAssureDx, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics' third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Insight Molecular Diagnostics' Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
FDA
CAUTION: This press release concerns certain products that are under clinical investigation, and which have not yet been cleared or authorized for marketing by the U.S. Food and Drug Administration. These products are currently limited by federal law to investigational use, and no representation is made as to the safety or effectiveness of these products for the purposes for which they are being investigated.
Investor Contact
Douglas Farrell
LifeSci Advisors LLC
imdx@lifesciadvisors.com
